Izilendustat hydrochloride
Modify Date: 2024-01-10 21:46:02
Izilendustat hydrochloride structure
|
Common Name | Izilendustat hydrochloride | ||
|---|---|---|---|---|
| CAS Number | 1303513-80-5 | Molecular Weight | 470.39 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C22H29Cl2N3O4 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Izilendustat hydrochlorideIzilendustat (hydrochloride) is a potent inhibitor of prolyl hydroxylase which stabilizes hypoxia inducible factor- 1 alpha (HIF- lα), as well as hypoxia inducible factor-2 (HIF-2). Izilendustat (hydrochloride) has the potential for the research of HIF- lα related diseases including Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, anemia, colitis, and other inflammatory bowel diseases (extracted from patent WO2011057115A1/WO2011057112A1/WO2011057121A1)[1][2][3]. |
| Name | Izilendustat hydrochloride |
|---|
| Description | Izilendustat (hydrochloride) is a potent inhibitor of prolyl hydroxylase which stabilizes hypoxia inducible factor- 1 alpha (HIF- lα), as well as hypoxia inducible factor-2 (HIF-2). Izilendustat (hydrochloride) has the potential for the research of HIF- lα related diseases including Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, anemia, colitis, and other inflammatory bowel diseases (extracted from patent WO2011057115A1/WO2011057112A1/WO2011057121A1)[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
prolyl hydroxylase[1] |
| References |
[1]. Joseph H, et al. Prolyl hydroxylase inhibitors. Patent WO2011057115A1. [3]. Joseph H, et al. Compositions and methods for treating colitis. Patent WO2011057121A1. |
| Molecular Formula | C22H29Cl2N3O4 |
|---|---|
| Molecular Weight | 470.39 |